Production of Medically Desirable Radioisotopes in the EIRENE Molten Salt Reactor
Radioisotopes play a vital role in nuclear medicine, enabling the performance of diagnostic procedures such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), in addition to innovative targeted therapies for selectively delivering cytotoxic radiation doses to tumor cells while minimizing damage to healthy tissue [1]. Beta emitting radionuclides such as 90Y and 131I find wide use in radio-immunotherapy, with the radiopharmaceuticals 90Y-ibritumomab tiuxetan (Zevalin®) and 131I-tositumomab (Bexxar®) having received FDA approval for treatment of non-Hodgkin’s lymphoma through targeting the CD20 surface receptor, which is commonly expressed in many B cell non-Hodgkin’s lymphoma subtypes [2, 3]. 90Y has also been successfully applied for treatment of brain tumors [4, 5] and liver cancer [6]. The favorable chelation chemistry of 90Y enables its use with a variety of ligands for the development of radiopharmaceuticals suitable for targeting different carcinoma types [1].